New Releases from NCBI BookshelfFutibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.​Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.

Post Content

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top